As recent reports described USP25 as an oncoprotein in diverse tumor entities [127,129], the co-inhibition of USP25 by the current available USP25/USP28 dual specific inhibitors for cancer therapy might, therefore, not be an issue. Here, USP28 is linked to cancer.